FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
25th March 2026 Uncategorised 0The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates.
More: FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
Source: fierce